We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Ravulizumab in myasthenic crisis: the first case report.
- Authors
Konen, Franz Felix; Jendretzky, Konstantin Fritz; Ratuszny, Dominica; Schuppner, Ramona; Sühs, Kurt-Wolfram; Pawlitzki, Marc; Ruck, Tobias; Meuth, Sven G.; Skripuletz, Thomas
- Abstract
This letter, published in the Journal of Neurology, presents a case report of a patient with generalized myasthenia gravis (MG) who experienced a severe myasthenic crisis. The patient was resistant to multiple standard therapies, including intravenous immunoglobulins (IVIg), immunoadsorption, and rituximab. However, the initiation of ravulizumab, a complement inhibitor, led to significant improvement in neuromuscular functions within a week. The patient's condition remained stable over a 19-week follow-up period, with further enhancements in quality of life observed. The authors suggest that complement inhibitors like ravulizumab may be a promising additional treatment strategy for refractory myasthenic crises, but further studies are needed to evaluate their effectiveness.
- Subjects
MYASTHENIA gravis; INTRAVENOUS immunoglobulins; PAROXYSMAL hemoglobinuria; MEDICAL care; MEDICAL research; HEMOLYTIC-uremic syndrome
- Publication
Journal of Neurology, 2024, Vol 271, Issue 5, p2898
- ISSN
0340-5354
- Publication type
Article
- DOI
10.1007/s00415-024-12234-2